A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer - ATLANTIC

Study identifier:D4191C00003

ClinicalTrials.gov identifier:NCT02087423

EudraCT identifier:2013-005427-16

CTIS identifier:2024-512379-10-00

Recruitment Complete

Official Title

A Phase II,Non-comparative,Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) who have received at least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

MEDI4736

Sex

All

Actual Enrollment

446

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 25 Feb 2014
Primary Completion Date: 03 Jun 2016
Estimated Study Completion Date: 28 Feb 2025

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria